| | | 20,000+ Fresh Resumes Monthly | |
|
|
| |
Click here or scroll down to respond to this candidate Candidate's Name , PhD
Street Address
Phone: PHONE NUMBER AVAILABLE
EMAIL AVAILABLE
CAREER PROFILE
Accomplished research associate with twelve years laboratory experience in drug discovery development in
pharmaceutical environments and eight years cancer research experience in academic area plus pharmacy
education and clinical research training background. Expertise in generating scientific reports/proposals and
developing assays/protocols to deliver relevant data. Experience in immunoassay, enzymatic and cell-based
techniques development and validation of assays for accuracy and reproducibility. Extensive knowledge and
skills in cancer cell biology, signal transduction, apoptosis, micro RNA, molecular biology, immunology and
oncology. Open and clear communicator at all levels with demonstrated business and strategic vision and
disciplined execution.
SKILLS
In vitro bioassays, signal Immunoassays, apoptosis
transduction assays
Enzymatic techniques; cell Cellular assay development
culture FACS / ELISA / PAGE /
Quality assurance/data PCR
accountability Method
Document archiving/result development/validation
publication
ATTRIBUTES
Maximized operational efficiency of project teams by conducting and analyzing
results of research. Implemented new assigned projects with high efficiency and performance
to achieve project goals.
As a project leader to present promising proposals to convince R&D decision-
making team at company headquarters in Japan to stage-up the project to next drug
development step.
As a lead author, published personal first paper in Science, with the novel
discovery of a natural product from grape with potential efficacy to prevent cancer.
EXPERIENCE
ASTELLAS RESEARCH INSTITUTE OF AMERICA, LLC Skokie, IL 2005 - 2013
Manager, Transplantation and Immunology 2011 to Present
Reported to Assistant Director, Transplantation and Immunology. Responsible for planning, performing,
monitoring, recording, reporting, and archiving laboratory studies to analyze clinical samples. Provided
reliable experimental data and scientific support in drug discovery and pre-clinical development stages.
Utilizing the skills in cell and molecular biology to investigate the molecular mechanism and
signal transduction to explore the potential novel targets for autoimmune diseases.
Prepared project proposals for further development of potential therapeutic compounds in drug
discovery research. Managed 5-6 study protocols simultaneously.
Proficient work competence in molecular bioassays (electrophoresis, PAGE, PCR, FACS), cell
culture assay techniques (cell plating, staining, and subculture).
Principal Scientist, Transplantation and Immunology 2005 2011
Followed GLP principles to perform laboratory studies and generate reliable and reproducible scientific data
to achieve project goals. Conducted research and analyzed data with SOP compliance to identify potential
biomarkers and provide input for selection of candidates for non-clinical studies development. Responsible
for data quality, accountability and timely data collection, documentation and reporting.
Generated development plans, experimental protocol designs and strategies for potential
compounds. Performed instrumentation validation and tracked reagent/material certification.
Conducted extensive experiments of immunoassays and molecular bioassays.
Candidate's Name , PhD Page Two
FUJISAWA RESEARCH INSTITUTE OF AMERICA Evanston, IL 2001 2005
Senior Scientist, Transplantation and Immunology 2002 2005
Provided instruction and management to project team members.
Developed effective working relationships with both colleagues and external contacts.
Identified and evaluated potential therapeutic targets for drug development by using extensive
laboratory techniques including ELISA, SDS-PAGE, Western Blot, PCR, RT-PCR, FACS, cell culture,
HPLC, GC, MS, UV etc.
As a key team member, ensured quality, data integrity and timeliness.
Scientist, Transplantation and Immunology 2001 2002
EDUCATION and TRAINING
2013 Advanced Post-Graduate Training Program in Clinical Research &
Pharmacovigilance
James Lind Institute, Montreal, Canada
1998 2001 Post Doctoral Fellow in cancer immunology
Medical Center, Loyola University, Maywood, IL, USA
Main research: Notch signaling in multimodality cancer therapy and
regulation of apoptosis and cell cycle pathways.
1998 PhD Pharmacognosy
University of Illinois at Chicago, Chicago, IL, USA
Thesis accomplishment: The first group to identify resveratrol
as a new cancer preventive agent from grape and published research work
in Science.
1990 BS Pharmacy
National Taiwan University, Taipei, Taiwan, ROC
PATENT
J.M. Pezzuto, R.C. Moon and M. Jang. Cancer chemopreventative composition and method. 1999
US Patent Number 6,008,260.
AFFILIATIONS
Healthcare Businesswomen s Association (HBA), Chicago Chapter, Program volunteer
ChemPharma Professional Association
Association of Clinical Research Professionals
Candidate's Name , PhD ADDENDUM
PUBLICATIONS
1. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR,
Kinghorn AD, Mehta RG, Moon RC, and Pezzuto JM. Cancer chemopreventive activity of
resveratrol, a natural product derived from grapes. Science, 275: PHONE NUMBER AVAILABLE
2. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Inoue H, Jang M, Pezzuto JM, and
Dannenberg AJ. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-
treated human mammary epithelial cells. J. Biol. Chem., 273: PHONE NUMBER AVAILABLE, 1998.
3. Jang M, and Pezzuto JM. Effects of resveratrol on 12-O-tetradecanoylphorbol-13-acetate-induced
oxidative events and gene expression in mouse skin. Cancer Lett., 134: 81-89, 1998.
4. Jang M, and Pezzuto JM. Resveratrol blocks eicosanoid production and chemically-induced cellular
transformation: Implications for cancer chemoprevention. Pharm. Biol., 36: 28-34, 1998.
5. Jang M, and Pezzuto JM. Cancer chemopreventive activity of resveratrol. Drugs Exp. Clin. Res., 25
65-77, 1999.
6. Jang M, Zlobin A, Kast WM, and Miele L. Notch signaling as a target in multimodality cancer
therapy. Curr. Opin. Mol. Ther., 2: 55-65, 2000.
7. Zlobin A, Jang M, and Miele L. Toward the rational design off cell fate modifiers: notch signaling as a
target for novel biopharmaceuticals. Curr. Pharm. Biotechnol., 1: 83-106, 2000.
8. Pan F, Ebbs A, Wynn C, Erickson L, Jang M, Crews G, Fisniku O, Kobayashi M, Paul LC,
Benediktsson H, and Jiang AH. FK778, a powerful new immunosuppressant, effectively reduces
functional and histologic changes of chronic rejection in rat renal allografts. Transplantation. 75:
1110-1114, 2003.
9. Jang M, Miao H, Carlesso N, Shelly L, Zlobin A, Darack N, Qin JZ, Nickoloff BJ, and Miele L. Notch-
1 regulates cell death independently of differentiation in murine erythroleukemia cells through
multiple apoptosis and cell cycle pathways. J. Cell Physiol. 199: PHONE NUMBER AVAILABLE
10. Erickson L, Crews G, Pan F, Fisniku O, Jang M, Wynn C, Kobayashi M, Jiang H. Unique gene
expression profiles of heart allograft rejection in the interferon regulatory factor-1-deficient
mouse. Transpl Immunol. 13(3):PHONE NUMBER AVAILABLE
11. Pan F, Fisniku O, Wynn C, Erickson LM, Crews G, Jang M, Sudo Y, Tamura K, Kobayashi M,
Benediktsson H, and Jiang H. PG490-88, a new immunosuppressant, effectively prevents
acute and chronic rejection in rat renal allografts. Transplant Proc. 37(1):134-136, 2005
12. Fisniku O, Pan F, Wynn C, Erickson LM, Crews G, Jang M, Sudo Y, Tamura K, Kobayashi M,
Benediktsson H, Jiang H. Protective effects of PG490-88 on chronic allograft rejection by
changing intragraft gene expression profiles. Transplant Proc. 37(4):1962-1964, 2005
13. Jiang H, Pan F, Erickson L, Jang M, Sanui T, Kunisaki Y, Sasazuki T, Kobayashi M, and Fukui Y.
Deletion of DOCK2, a regulator of the actin cytoskeleton in lymphocytes, suppresses cardiac
allograft rejection. J. Exp. Med., 202: 1121-1130, 2005.
14. Jang M, Pan F, Erickson L, Fisniku O, Crews G, Wynn C, Hong IC, Tamura K, Kobayashi M, and
Jiang H. A blocking anti-CD28-specific antibody induces long-term heart allograft survival by
suppression of the PKC theta-JNK signal pathway. Transplantation, 85: 1051-1055, 2008.
|
